A recent study reveals that individuals who stop using popular slimming jabs like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt traditional lifestyle programs.
Findings released in a leading medical journal demonstrates that while obese people can lose substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People buying these drugs must be aware of the danger of fast weight regain when the medication ends," warns researcher Dr. Susan Jebb.
That rate of regain implies a reversion to starting mass in about one and a half years.
Weighing Approaches
The analysis, which looked at 37 of trials involving thousands of patients, compared the outcomes of the injectable medications with other pills.
Researchers point out that people who shed pounds through lifestyle changes alone usually have a more gradual creep back—approximately 0.1 kg a month—once they finish.
Understanding the Quick Regain
Experts propose the mode of action of the jabs explains the accelerated weight return.
The injections imitate a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
Health authorities recommend the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of relapse, the therapy is often long-term.
This perspective is reinforced by drug manufacturers, who say that the results "underscore the long-term character of excess weight," similar to managing diseases like high blood pressure.
User Experiences
Users who have stopped the jabs report a sudden return of hunger.
"It felt as if a trigger activating and you become ravenous," described an individual.
This difficulty is exacerbated if patients have not established sustainable lifestyle or habit changes during treatment.
Widespread Interest
Survey data show that millions of adults in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is higher among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, experts stress that while the jabs are powerful agents for weight loss, they are not a standalone solution and maintained weight loss hinges on combined behavioural changes.
